(Albany, United States) DelveInsight’s ‘Prostate Cancer Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Prostate Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Prostate Cancer pipeline domain.
For Prostate Cancer emerging drugs, the Prostate Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Prostate Cancer Pipeline Report
- DelveInsight’s Prostate Cancer Pipeline analysis depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Prostate Cancer treatment.
- The leading Prostate Cancer companies include Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others are evaluating their lead assets to improve the Prostate Cancer treatment landscape.
- Key Prostate Cancer pipeline therapies in various stages of development include Pembrolizumab, Talazoparib, ODM-208, ZEN 3694, EPI-7386, RV 001, Adavosertib, Capivasertib, ADXS31-142, TRC253, Nivolumab, LAE001, BR55, ARV-110, Tazemetostat, REGN5678, VERU-111, Abemaciclib, Cabozantinib, LY01005, Tarlatamab, VT-464, BAY2315497, NX-1207, MBM-02, TAVT-45, FOR46, JNJ-78278343, 64Cu-SAR-bisPSMA, DKN-01, HC-1119, ChAdOx1-MVA 5T4, Onvansertib, GT0918, TNB-585, JANX007, 225Ac-PSMA I&T, CRB-701, BXCL701, AsiDNA, ADXS-504, HB-300, NUV-868, ARX517, JMKX002992, Zilovertamab, IMU-935, BNT112, and others.
- In June 2023, Talzenna (talazoparib) in combination with Xtandi (enzalutamide) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer.
- In February 2023, Fusion Pharmaceuticals announced the acquisition from RadioMedix, Inc. of the investigational new drug application for an ongoing Phase II clinical trial (the “TATCIST” trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen (“PSMA”) expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial will be known as FPI-2265.
- In February 2023, Corbus Pharmaceuticals entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited for development and commercialization of CRB-701 (SYS6002): a novel clinical-stage antibody drug conjugate (ADC) targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia. CSPC will retain all rights to SYS6002 in the remaining global markets. Clinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid tumors, potentially including lung, breast and prostate cancer.
- In February 2023, BioXcel Therapeutics, Inc.reported full data from its Phase IIa trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.
- In January 2023, Onxeo S.A. gave an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first US clinical study site, Next Oncology San Antonio. This phase I/II multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients with recurrent ovarian, breast, and metastatic castration-resistant prostate cancer (mCRPC) who have progressed on previous PARP inhibitor therapy.
Request a sample and discover the recent breakthroughs happening in the Prostate Cancer pipeline landscape @ Prostate Cancer Pipeline Outlook
Prostate Cancer Overview
Prostate cancer is a type of cancer that arises from the prostate gland. It is the second leading cause of cancer death in men in the United States. 1 in every 9 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer will be diagnosed in nearly 250,000 men this year. Breaking away from a prostate tumor allows prostate cancer cells to spread. They can spread to other body parts by passing through blood vessels or lymph nodes. Cancer cells that have spread may attach to other tissues and grow to form new tumors, causing damage wherever they land.
Prostate cancer symptoms vary from person to person. Some men have no symptoms at all. Common prostate cancer symptoms include blood in the urine or semen, painful ejaculation, pain or burning during urination, and others. A biopsy is a primary tool for prostate cancer diagnosis, but a doctor can use other tools to ensure that the biopsy is performed in the correct location. Doctors may, for example, use transrectal ultrasound or magnetic resonance imaging (MRI) to guide the biopsy.
Find out more about Prostate Cancer medication @ New Drug for Prostate Cancer
Prostate Cancer Treatment Analysis: Drug Profile
Pembrolizumab: Merck & Co
Keytruda (pembrolizumab) is a humanized monoclonal antibody that prevents PD-1 from interacting with its ligands, PD-L1 and PD-L2. T cell proliferation and cytokine production are inhibited when the PD-1 ligands, PD-L1 and PD-L2, bind to the PD-1 receptor located on T cells. In some tumors, PD-1 ligands are upregulated, and signaling through this route can contribute to the suppression of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and inhibits its interaction with PD-L1 and PD-L2, hence inhibiting the immunological response, including the anti-tumor immune response. It is currently in phase 3 development to treat prostate cancer.
Talazoparib: Pfizer
Talazoparib is a PARP enzyme inhibitor that aids in DNA repair. Preclinical research suggests that talazoparib works by inhibiting PARP enzyme activity and trapping PARP at the site of DNA damage, resulting in decreased cancer cell proliferation and death. Talazoparib also showed anti-tumor efficacy in animal models of human breast cancer that contained mutant or non-mutated BRCA1/2.
Key Prostate Cancer Therapies and Companies
- Pembrolizumab: Merck & Co
- Talazoparib: Pfizer
- Capivasertib: AstraZeneca
- VERU-111: Veru Healthcare
- MBM-02: Matrix Biomed
- ZEN 3694: Zenith Epigenetics
- Onilcamotide : RhoVac
- IMMU-132: Gilead Sciences
- PT-112: Promontory Therapeutics
- EPI-7386: ESSA Pharma
- REGN4336: Regeneron Pharmaceuticals
- HB-302: Hookipa Biotech
- BNT112: BioNTech SE
- AMG 509: Amgen
- JANX007: Janux Therapeutics
- ORIC-944: ORIC Pharmaceuticals
Learn more about the novel and emerging Prostate Cancer pipeline therapies @ Prostate Cancer Clinical Trials
Prostate Cancer Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Prostate Cancer Pipeline Report
- Coverage: Global
- Key Prostate Cancer Companies: Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.
- Key Prostate Cancer Pipeline Therapies: Pembrolizumab, Talazoparib, ODM-208, ZEN 3694, EPI-7386, RV 001, Adavosertib, Capivasertib, ADXS31-142, TRC253, Nivolumab, LAE001, BR55, ARV-110, Tazemetostat, REGN5678, VERU-111, Abemaciclib, Cabozantinib, LY01005, Tarlatamab, VT-464, BAY2315497, NX-1207, MBM-02, TAVT-45, FOR46, JNJ-78278343, 64Cu-SAR-bisPSMA, DKN-01, HC-1119, ChAdOx1-MVA 5T4, Onvansertib, GT0918, TNB-585, JANX007, 225Ac-PSMA I&T, CRB-701, BXCL701, AsiDNA, ADXS-504, HB-300, NUV-868, ARX517, JMKX002992, Zilovertamab, IMU-935, BNT112, and others.
Dive deep into rich insights for drugs used for Prostate Cancer treatment; visit @ Prostate Cancer Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Prostate Cancer Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Prostate Cancer Pipeline Therapeutics |
| 6. | Prostate Cancer Pipeline: Late Stage Products (Phase III) |
| 7. | Prostate Cancer Pipeline: Late Stage Products (Phase III) |
| 8. | Prostate Cancer Pipeline: Mid-Stage Products (Phase II) |
| 9. | Prostate Cancer Pipeline: Early Stage Products (Phase I) |
| 10. | Prostate Cancer Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Prostate Cancer Companies |
| 14. | Key Prostate Cancer Products |
| 15. | Prostate Cancer Unmet Needs |
| 16. | Prostate Cancer Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Prostate Cancer therapy in the pipeline, reach out @ Prostate Cancer Medication
Related Reports
Metastatic Prostate Cancer Pipeline
Metastatic Prostate Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key metastatic prostate cancer companies, including Veru, Tracon, Sotio, among others.
Metastatic Castration-Sensitive Prostate Cancer Pipeline
Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key metastatic castration-sensitive prostate cancer companies, including Merck, Pfizer, Veru, Tracon, Sotio, among others.
Metastatic Hormone-Refractory Prostate Cancer Pipeline
Metastatic Hormone-Refractory Prostate Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key metastatic hormone-refractory prostate cancer companies, including Merck, Pfizer, Veru, Tracon, Sotio, among others.
Metastatic Castration-Resistant Prostate Cancer Epidemiology Forecast
Metastatic Castration-Resistant Prostate Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the metastatic castration-resistant prostate cancer epidemiology trends.
Metastatic Castration-Resistant Prostate Cancer Market
Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic castration-resistant prostate cancer companies including Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Regeneron Pharmaceuticals, Veru Inc, among others.
Trending Report:
France Healthcare Outlook Report | Acute Pulmonary Embolism Market | Choroidal Neovascularization Market | Chronic Cutaneous Ulcer Market | Pulse Oximeters Market | Ankylosing Spondylitis Market | Neuroblastoma Market | Eczema Market | Chemotherapy Induced Thrombocytopenia Market | Ncfb Market | Pruritus Market | Achondroplasia Market | Blood Gas And Electrolyte Analyzers Market | Hyperinsulinemic Hypoglycemia Market | Alpha Antitrypsin Market | Concussions Market Size | Stable Angina Market | Allergic Conjunctivitis Market | Encephalitis Market | Intrahepatic Cholangiocarcinoma Market | Acute Coronary Syndrome Market | Advanced Renal Cell Carcinoma Market | Angioedema Market | Anemia Market | Foot And Ankle Devices Market | Giant Papillary Conjunctivitis Market | Hepatorenal Syndrome Market | Optic Neuritis Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187